510(k) for In Vitro Diagnostics (IVD): What's Different

In vitro diagnostic devices — tests that analyze samples taken from the human body — follow the 510(k) framework for substantial equivalence but have a distinct set of requirements that differ significantly from therapeutic or monitoring devices. If you're developing an IVD, understanding these differences before you begin predicate research will save significant time.

IVD predicate selection: the analyte matters most

For IVD devices, the primary basis for predicate selection is the analyte being measured — not just the device type or physical configuration. An IVD 510(k) for a glucose test must cite a predicate that also measures glucose. A test that measures a different biomarker, even if the assay technology is identical, is not an appropriate predicate for the intended use.

Secondary predicate considerations for IVDs include the specimen type (whole blood vs plasma vs urine), the intended use setting (point of care vs laboratory), the intended patient population, and the quantitative or qualitative nature of the result.

Analytical validation requirements

Where a standard device 510(k) requires bench testing of mechanical or electrical performance, an IVD 510(k) requires analytical validation — a set of studies that demonstrate the test performs as claimed across the range of conditions it will encounter in use.

Standard analytical validation studies for a quantitative IVD include:

• Precision — repeatability (within-run) and reproducibility (between-run, between-site, between-day)
• Accuracy/method comparison — comparison to a reference method or predicate device using patient samples
• Linearity/analytical measurement range — the range over which the test produces quantitatively accurate results
• Interference — substances commonly found in patient samples (hemoglobin, bilirubin, lipids, common drugs) that could affect results
• Reference intervals — normal ranges established in representative population samples
• Stability — reagent stability at claimed storage conditions, open-vial stability, onboard stability

IVD-specific labeling: 21 CFR Part 809

IVD devices are subject to 21 CFR Part 809 in addition to general device labeling requirements under 21 CFR Part 801. Part 809 requires specific labeling elements that are not required for other devices, including: a complete description of the test principle, the intended use and indications, a summary of performance characteristics, limitations of the procedure, and specific warnings for interpretive errors.

Labeling inconsistencies between Part 809 elements and the rest of your submission are a common AI trigger for IVD 510(k)s. In particular, the limitations section in labeling must be consistent with the interference data in your analytical validation.

Point-of-care vs laboratory IVDs

IVDs intended for use at the point of care (physician office, hospital bedside, home) have additional requirements compared to laboratory-only devices. Point-of-care tests must demonstrate usability by intended users — often non-laboratory personnel — and must address the risk of user error in their design and labeling. Usability testing or user comprehension studies are often expected in POC IVD submissions even when not explicitly required.